Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients With Severe COVID-19

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deramiocel (Primary)
Indications COVID 2019 infections; Respiratory tract infections
Focus Adverse reactions; Expanded access; Therapeutic Use
Sponsors Capricor

Most Recent Events

07 Oct 2020 Status changed from recruiting to completed.
29 Apr 2020 Results (n=6) presented in the Capricor Therapeutics media release.
29 Apr 2020 According to a Capricor Therapeutics media release, the U.S. Food and Drug Administration (FDA) approved the Company's expanded access protocol to treat up to 20 additional COVID-19 patients. Data (n=6) from this trial has been submitted for publication.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com